Tuesday, September 15, 2020
Capsule Technologies has received FDA 510(k) clearance for its Vitals Plus monitoring solution with the Masimo NomoLine ISA CO2 Module, the company announced today.
Capnography technology enables clinicians to continuously monitor patient end-tidal carbon dioxide (EtCO2), respiratory rate (RR) and fractional inspired CO2 (FiCO2) for ventilation adequacy and the onset of changes in patients’ cardiovascular and respiratory conditions. Capnography is used to assess hypoventilation and hyperventilation, which is particularly important as an indicator of respiratory depression or impending respiratory failure and arrest. Capnography is commonly used to assess the return of spontaneous circulation after cardiac arrest and has applications across the care spectrum, in both high and low acuity settings, from surgery and intensive care to the general care unit and emergency departments.
Vitals Plus with NomoLine capnography measures the concentration of expired carbon dioxide (CO2) in an exhaled breath — an immediate indicator of ventilation and respiratory adequacy. The concentration or partial pressure of exhaled CO2 provides information about the body’s metabolism, perfusion, pulmonary circulation and cardiac function. The technology can also be used in conjunction with Capsule’s Early Warning Scoring System (EWSS) to enable another layer of protection and alerts for caregivers when deterioration is beginning to happen.
Masimo is a leading global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies. Its NomoLine sidestream technology, used with Vitals Plus monitoring, eliminates common problems associated with conventional side stream gas analyzers, including the need for water traps and issues related to their handling.
Capsule’s Vitals Plus monitors a patient and sends validated or unvalidated vital signs data to the electronic health record (EHR) right from the bedside, enabling clinicians to focus on direct caregiving. When linked with Capsule Surveillance, Vitals Plus and other medical devices can feed critical patient information to surveillance algorithms that intelligently alert caregivers to important changes in patient status. The capnography module can be shared between multiple monitors to provide flexibility based on patient needs. The capnography module also will be available as an accessory that can be added to specific Vitals Plus monitors already in hospitals.
About Capsule Technologies
Capsule Technologies is a leading global provider of medical data technologies for hospitals and healthcare organizations. Our Medical Device Information Platform — comprised of device integration, vital signs monitoring, and clinical surveillance solutions — captures streaming clinical data from connected systems and transforms it into context-rich information for clinical documentation, alarm management, patient surveillance, decision support, predictive analytics, clinical research and more. End-to-end data management and connectivity supports better collaboration and communication between clinicians and departments. More than 2,900 global clients leverage our platform to improve patient safety, simplify workflows and raise overall satisfaction throughout the hospital and across care settings. Learn more at www.capsuletech.com.
Amendola Communications for Capsule Technologies, Inc.